Richard Kennedy

Richard Kennedy is a Professor at Queen’s University Belfast’s School of Medicine, Dentistry and Biomedical Sciences, affiliated with the Patrick G Johnston Centre for Cancer Research. His research focuses on precision medicine, immune oncology, and DNA repair mechanisms in cancer. He leads the Stratified Medicine Group, targeting biomarker development for anti-angiogenic agents and prognostic markers in prostate and ovarian cancers.

Affiliations:

• Professor, Queen’s University Belfast
• Principal Investigator in multiple research projects (e.g., Future Medicines Institute, Precision Medicine Catapult Centre)

Research Interests:

• Characterization of innate immune responses via the STING pathway in solid cancers
• Development of biomarkers for MEKK pathway activation and anti-angiogenic therapies
• Pre-clinical modeling of ovarian and prostate cancers
• Integration of genomic data and clinical trials

Key Projects:

• Future Medicines Institute (2024–present)
• Precision Medicine Catapult Centre of Excellence (2017–present)
• National Digital Pathology Platform for Solid Tumors (2015–present)

Awards:

• Queen’s University Vice Chancellor Award for Innovation (2013)
• St Luke’s Medal for Cancer Research (2015)

Grants & Collaborations:

• Principal Investigator in multi-institutional projects (e.g., DEBIOC clinical trial)
• Partnerships with Almac, Northern Ireland Cancer Centre, and international institutions

Labs & Teams:

• Stratified Medicine Group at Queen’s University
• Collaborations with the Centre for Public Health and the Northern Ireland Cancer Centre